BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 31928356)

  • 1. Galactose-modified selenium nanoparticles for targeted delivery of doxorubicin to hepatocellular carcinoma.
    Xia Y; Zhong J; Zhao M; Tang Y; Han N; Hua L; Xu T; Wang C; Zhu B
    Drug Deliv; 2019 Dec; 26(1):1-11. PubMed ID: 31928356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functionalized selenium nanoparticles for targeted delivery of doxorubicin to improve non-small-cell lung cancer therapy.
    Xia Y; Chen Y; Hua L; Zhao M; Xu T; Wang C; Li Y; Zhu B
    Int J Nanomedicine; 2018; 13():6929-6939. PubMed ID: 30464451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxorubicin-loaded functionalized selenium nanoparticles for enhanced antitumor efficacy in cervical carcinoma therapy.
    Xia Y; Xiao M; Zhao M; Xu T; Guo M; Wang C; Li Y; Zhu B; Liu H
    Mater Sci Eng C Mater Biol Appl; 2020 Jan; 106():110100. PubMed ID: 31753388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel functionalized nanoparticles for tumor-targeting co-delivery of doxorubicin and siRNA to enhance cancer therapy.
    Xia Y; Xu T; Wang C; Li Y; Lin Z; Zhao M; Zhu B
    Int J Nanomedicine; 2018; 13():143-159. PubMed ID: 29317822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivery of Doxorubicin for Human Cervical Carcinoma Targeting Therapy by Folic Acid-Modified Selenium Nanoparticles.
    Xia Y; Xu T; Zhao M; Hua L; Chen Y; Wang C; Tang Y; Zhu B
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30428576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyaluronic acid-modified selenium nanoparticles for enhancing the therapeutic efficacy of paclitaxel in lung cancer therapy.
    Zou J; Su S; Chen Z; Liang F; Zeng Y; Cen W; Zhang X; Xia Y; Huang D
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3456-3464. PubMed ID: 31469318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective cellular uptake and induction of apoptosis of cancer-targeted selenium nanoparticles.
    Huang Y; He L; Liu W; Fan C; Zheng W; Wong YS; Chen T
    Biomaterials; 2013 Sep; 34(29):7106-16. PubMed ID: 23800743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional Doxorubicin-Loaded Omega-3 Unsaturated Fatty Acids Nanoparticles in Reversing Hepatocellular Carcinoma Multidrug Resistance.
    Wang C; Wei X; Shao G
    Med Sci Monit; 2021 Feb; 27():e927727. PubMed ID: 33524008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insight into the role of dual-ligand modification in low molecular weight heparin based nanocarrier for targeted delivery of doxorubicin.
    Du H; Liu M; Yu A; Ji J; Zhai G
    Int J Pharm; 2017 May; 523(1):427-438. PubMed ID: 28359815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TPGS-Galactose-Modified Polydopamine Co-delivery Nanoparticles of Nitric Oxide Donor and Doxorubicin for Targeted Chemo-Photothermal Therapy against Drug-Resistant Hepatocellular Carcinoma.
    Du Z; Mao Y; Zhang P; Hu J; Fu J; You Q; Yin J
    ACS Appl Mater Interfaces; 2021 Aug; 13(30):35518-35532. PubMed ID: 34286569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. siRNA-loaded selenium nanoparticle modified with hyaluronic acid for enhanced hepatocellular carcinoma therapy.
    Xia Y; Guo M; Xu T; Li Y; Wang C; Lin Z; Zhao M; Zhu B
    Int J Nanomedicine; 2018; 13():1539-1552. PubMed ID: 29588583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doxorubicin-Loaded Carbon Dots Lipid-Coated Calcium Phosphate Nanoparticles for Visual Targeted Delivery and Therapy of Tumor.
    Zhang J; Zhang H; Jiang J; Cui N; Xue X; Wang T; Wang X; He Y; Wang D
    Int J Nanomedicine; 2020; 15():433-444. PubMed ID: 32021189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence.
    Zhang F; Jia Y; Zheng X; Shao D; Zhao Y; Wang Z; Dawulieti J; Liu W; Sun M; Sun W; Pan Y; Cui L; Wang Y; He K; Zhang M; Li J; Dong WF; Chen L
    Acta Biomater; 2019 Dec; 100():352-364. PubMed ID: 31563690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin.
    Mezghrani O; Tang Y; Ke X; Chen Y; Hu D; Tu J; Zhao L; Bourkaib N
    Int J Pharm; 2015 Jan; 478(2):553-68. PubMed ID: 25455765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual-targeting nanoparticles with core-crosslinked and pH/redox-bioresponsive properties for enhanced intracellular drug delivery.
    Zhao J; Yan C; Chen Z; Liu J; Song H; Wang W; Liu J; Yang N; Zhao Y; Chen L
    J Colloid Interface Sci; 2019 Mar; 540():66-77. PubMed ID: 30634060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functionalized selenium nanoparticles for targeted siRNA delivery silence Derlin1 and promote antitumor efficacy against cervical cancer.
    Xia Y; Tang G; Wang C; Zhong J; Chen Y; Hua L; Li Y; Liu H; Zhu B
    Drug Deliv; 2020 Dec; 27(1):15-25. PubMed ID: 31830840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reductively degradable α-amino acid-based poly(ester amide)-graft-galactose copolymers: facile synthesis, self-assembly, and hepatoma-targeting doxorubicin delivery.
    Lv J; Sun H; Zou Y; Meng F; Dias AA; Hendriks M; Feijen J; Zhong Z
    Biomater Sci; 2015 Jul; 3(7):1134-46. PubMed ID: 26221946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo effect of hyaluronic acid modified, doxorubicin and gallic acid co-delivered lipid-polymeric hybrid nano-system for leukemia therapy.
    Shao Y; Luo W; Guo Q; Li X; Zhang Q; Li J
    Drug Des Devel Ther; 2019; 13():2043-2055. PubMed ID: 31388296
    [No Abstract]   [Full Text] [Related]  

  • 19. Redox-responsive mesoporous selenium delivery of doxorubicin targets MCF-7 cells and synergistically enhances its anti-tumor activity.
    Zhao S; Yu Q; Pan J; Zhou Y; Cao C; Ouyang JM; Liu J
    Acta Biomater; 2017 May; 54():294-306. PubMed ID: 28267598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiotherapy-induced enrichment of EGF-modified doxorubicin nanoparticles enhances the therapeutic outcome of lung cancer.
    Wang J; Zhang Y; Zhang G; Xiang L; Pang H; Xiong K; Lu Y; Li J; Dai J; Lin S; Fu S
    Drug Deliv; 2022 Dec; 29(1):588-599. PubMed ID: 35156493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.